Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.55 |
| ▸ | CYP17A1 | P05093 | 6/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5132733 | 0.84 | CHRNB2 (0.47) | CHRNB2CHRNA4CYP17A1CYP3A4CYP11B2 | |
| SCHEMBL20874477 | 0.83 | GID4 (0.56) | CYP17A1CYP3A4CYP11B2CYP11B1CYP19A1 | |
| SCHEMBL15495498 | 0.75 | CHRNB2 (0.58) | CHRNB2CHRNA4CYP3A4SIGMAR1CHRNA7 | |
| SCHEMBL12993347 | 0.75 | CHRNB2 (0.58) | CHRNB2CHRNA4CYP11B2CYP11B1SIGMAR1 | |
| SCHEMBL30557113 | 0.75 | CHRNB2 (0.63) | CHRNB2CHRNA4CYP3A4SIGMAR1CHRNA7 | |
| SCHEMBL23756600 | 0.75 | CHRNB2 (0.58) | CHRNB2CHRNA4CYP11B2CYP11B1SIGMAR1 | |
| SCHEMBL2669664 | 0.75 | CHRNB2 (0.58) | CHRNB2CHRNA4CYP11B2CYP11B1SIGMAR1 | |
| SCHEMBL7258173 | 0.75 | CHRNB2 (0.58) | CHRNB2CHRNA4CYP3A4CYP11B2CYP11B1 | |
| SCHEMBL16363087 | 0.75 | CHRNB2 (0.58) | CHRNB2CHRNA4CYP3A4CYP11B2CYP11B1 | |
| SCHEMBL12891530 | 0.75 | CHRNB2 (0.63) | CHRNB2CHRNA4SIGMAR1CHRNA7FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076784-A1 | Bicyclic, Nitrogen-Containing Heterocycles and Aromatase Inhibitors | NOVARTIS AG (CH) | 2008-03-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076784-A1 | Bicyclic, Nitrogen-Containing Heterocycles and Aromatase Inhibitors | CYP19A1, NR5A1, HSD17B11 | CHRNB2 2127/4885CHRNA4 2380/4885CYP17A1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.